Analysis suggests tumor histology plays an important role in determining the best first-line approach for patients who have non–small cell lung cancer (NSCLC).
New agents in development including ABBV-011 and BL-B01D1 seek to turn the tides of relapsed extensive-stage small cell lung cancer; although chemoimmunotherapy has earned its right as the frontline standard of care, both classes of agents have yet to demonstrate benefit in second or later lines.
Amivantamab elicited an objective response rate of 37% per investigator assessment, with a median duration of response of 12.5 months, according to long-term data from the CHRYSALIS trial.
NZ-AU: Immutep Quarterly Activities Report livenews.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livenews.co.nz Daily Mail and Mail on Sunday newspapers.
First-line treatment with furmonertinib plus icotinib induced responses in patients with EGFR-mutant non–small cell lung cancer. including those with central nervous system metastases, according to data from an ongoing phase 2 trial.